DEF: SCWorx Seeks Shareholder Approval for Major Dilutive Capital Raises

SCWorx Corp. will hold its annual meeting on December 8, 2025, seeking shareholder approval for significant dilutive equity issuances, a substantial increase in authorized shares, and a new equity incentive plan.

Summary

• Shareholders are requested to elect four directors: Tim Hannibal, Vincent Matozzo, Michael Burke, and Troy Kirchenbauer.
• A non-binding, advisory vote on the compensation of named executive officers is proposed.
• The selection of Astra Audit & Advisory, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025, is up for ratification, following the termination of previous auditor BF Borgers CPA PC due to an SEC order.
• Approval is sought to authorize the issuance of 21,988,638 shares of Common Stock upon exercise of warrants from a January 21, 2025, private investment, at an exercise price of $0.3496 per share, to comply with Nasdaq Listing Rule 5635(d).
• Shareholder approval is requested for the issuance of 4,128,000 shares of Common Stock upon exercise of Series A common stock purchase warrants (Reload Warrants) from September 17, 2025, inducement agreements, at an exercise price of $0.31004 per share, also for Nasdaq compliance.
• A proposal to authorize the future issuance of shares upon conversion of up to $1,500,000 in convertible promissory notes and exercise of warrants to purchase up to 30,000,000 shares of Common Stock, at prices below the Minimum Price, is presented for Nasdaq compliance.
• An amendment to the company's certificate of incorporation is proposed to increase the total authorized shares from 45,000,000 to 155,000,000, with 150,000,000 shares designated as Common Stock.
• The adoption of the 2025 Equity Incentive Plan, reserving up to 10,000,000 shares of Common Stock for issuance, is also proposed to attract and retain key employees and service providers.

Sentiment

Score: 3

Explanation: The filing indicates a company in continuous need of highly dilutive capital raises to fund its operations, evidenced by multiple proposals for issuing shares below market price and a significant increase in authorized shares. While management is seeking necessary approvals to continue operations, the reliance on such financing and the substantial dilution for existing shareholders are significant concerns. The termination of the previous auditor due to SEC action also adds a layer of negative sentiment regarding financial integrity.

Positives

• The company is seeking to ratify a new independent auditor, Astra Audit & Advisory, LLC, after terminating its previous auditor due to an SEC order, which could improve financial reporting credibility.
• The proposed 2025 Equity Incentive Plan aims to attract, motivate, and retain key employees and service providers by aligning their interests with shareholders through equity awards.
• The Board of Directors includes experienced executives in technology, supply chain, and healthcare finance, which could provide valuable strategic guidance.

Negatives

• The company is seeking approval for multiple significant dilutive equity issuances (Proposals 4, 5, and 6), which will substantially increase the number of outstanding shares and reduce current shareholders' percentage ownership.
• The warrants and convertible notes are being issued at prices below the Nasdaq 'Minimum Price,' indicating a low valuation and potentially unfavorable financing terms.
• The proposed increase in authorized common stock from 45,000,000 to 150,000,000 shares (Proposal 7) suggests a high likelihood of further significant dilution in the future.
• The company explicitly states that failure to approve these dilutive capital raise proposals could jeopardize its ability to execute its business plan, indicating a reliance on such financing for continued operations.
• The previous auditor, BF Borgers CPA PC, was denied the privilege of practicing before the SEC, raising concerns about the integrity of past financial statements.

Risks

• Failure to approve Proposal No. 4 (January 2025 Warrants) would prevent the company from receiving approximately $7.7 million upon warrant exercise, potentially jeopardizing its business plan.
• Failure to approve Proposal No. 5 (Warrant Inducement) would mean Reload Warrants are not exercisable in a manner compliant with Nasdaq Rule 5635(d).
• Failure to approve Proposal No. 6 (Future Offering) would prevent the company from issuing shares for future convertible notes and warrants, potentially making it unable to fund business activities.
• Significant dilution of current shareholders' percentage ownership, voting power, liquidation value, book and market value, and future earnings due to the issuance of shares from warrants and convertible notes.
• The issuance or resale of Common Stock to warrant holders could cause the market price of the company's Common Stock to decline.
• The increase in authorized shares (Proposal 7) may have an incidental anti-takeover effect by allowing additional shares to dilute stock ownership of parties seeking control.
• The company's reliance on dilutive financing methods to fund its business plan poses a continuous risk to shareholder value.
• The termination of the former auditor due to an SEC order highlights potential risks related to financial reporting and compliance.

Future Outlook

The company anticipates needing additional authorized shares for future capital raising activities, potential acquisitions, and its proposed 2025 Equity Incentive Plan. It expects to undertake a future offering of convertible notes and warrants (up to $1.5 million) with terms substantially similar to previous dilutive issuances, stating that this may be the only viable financing alternative available to fund its business plan.

Management Comments

• "After extensive efforts to raise capital on more favorable terms, we believed that the Private Investment was the only viable financing alternative available to us at the time."
• "Loss of these potential funds could jeopardize our ability to execute our business plan."
• "We believe that the Future Offering may be the only viable financing alternative available to us at that time."
• "We believe that this structure [CEO, CFO, Chairman of Board] provides an efficient and effective leadership model for the Company."

Industry Context

SCWorx operates in the healthcare technology and supply chain sector, as indicated by the professional backgrounds of its directors. The company's continuous reliance on highly dilutive financing, including multiple proposals for equity issuances at prices below market value, suggests significant challenges in achieving sustainable profitability or securing less dilutive funding. While the industry is trending towards digital transformation and advanced analytics in supply chain management, the company's financial strategy appears to be struggling to keep pace or capitalize effectively on these trends without substantial shareholder dilution.

Management Changes

Corporate Governance

Legal Proceedings

• BF Borgers CPA PC, the company's independent registered public accounting firm from April 2021 through May 2024, was denied the privilege of appearing or practicing before the SEC as an accountant by an SEC Order. The company subsequently terminated BF Borgers as its auditor.

Related Party Transactions

• Amounts due to officers totaled $149,838 as of December 31, 2024.
• The company had balances of $67,622 included in stockholder advance as of December 31, 2024, and 2023, stemming from a $100,000 non-interest bearing, demand-payable advance from the former CEO in September 2021.
• The CFO advanced an aggregate of $128,479 in cash to the company for short-term capital requirements between January 18, 2024, and July 11, 2024, which was fully repaid by December 31, 2024.

Stakeholder Impact

• **Shareholders**: Face significant dilution from past and proposed equity issuances, potentially reducing their percentage ownership, voting power, liquidation value, and market value. Their approval is critical for the company's continued financing.
• **Employees/Service Providers**: Will benefit from the proposed 2025 Equity Incentive Plan, which aims to attract, motivate, and retain key talent through equity awards.
• **Investors (Warrant/Note Holders)**: Will benefit from the exercise of warrants and conversion of notes, potentially at prices below market, and from anti-dilution provisions. Their ability to exercise depends on shareholder approval.
• **Creditors**: The capital raises are intended to fund business activities, which could improve the company's ability to meet its obligations, but the continuous need for dilutive financing may also signal underlying financial instability.

Next Steps

• The Annual Meeting of Shareholders will be held on December 8, 2025, to vote on the proposed matters.
• If approved, the Board of Directors will be able to issue additional Common Stock up to a total of 150,000,000 shares without further shareholder action.
• If approved, the 2025 Equity Incentive Plan will become effective immediately, subject to share availability.
• The company intends to mail the proxy statement and the 2024 annual report to shareholders around October 28, 2025.
• The company expects to enter into a Securities Purchase Agreement for the Future Offering at a future date, with an anticipated transaction timeframe of approximately three months.
• If the Reload Warrants are approved, the company will file a registration statement for the resale of the New Warrant Shares within 30 days of the Stockholder Approval Date and use commercially reasonable efforts to have it declared effective by the SEC within 60 to 90 days.

Key Dates

Recommendation

The company is seeking approval for multiple highly dilutive equity issuances, including past warrants and a future offering, explicitly stating these are necessary to fund its business plan and may be the only viable financing options. The proposed increase in authorized shares from 45 million to 150 million further signals a strong intent for future dilution. The current stock price of $0.275 and the continuous need for capital raises at prices below the 'Minimum Price' (Nasdaq's threshold for significant dilution) indicate severe financial distress and a high risk of further value erosion for existing shareholders. The termination of the previous auditor due to SEC action also raises concerns about financial reporting integrity. While the company is attempting to secure its future, the methods employed are highly detrimental to current shareholder value, making it a 'sell' for a seasoned investor.

Keywords

SCWorx, SEC filing, DEF 14A, proxy statement, shareholder meeting, equity issuance, warrants, convertible notes, stock dilution, Nasdaq compliance, capital raise, corporate governance, executive compensation, auditor ratification, equity incentive plan